BriaCell Therapeutics: Funding, Investors & Team (Sep 2026)
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. The company's patented immunotherapy Bria-IMT™ is developed from a breast cancer cell line is an immunotherapy approach that directly stimulates the body’s own cancer-fighting cells to attack and destroy breast cancer tumors. It induces an antitumor response both indirectly and directly by stimulating the immune system which collectively boosts the body’s response. BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™ in a combination with retifanlimab and epacadostat. The company is developing Bria-OTS™, the first “off the shelf” personalized immunotherapy for advanced breast cancer. It is founded in New York, New York in 2004.
BriaCell Therapeutics has raised $75.8M across 8 funding rounds on record, the most recent an undisclosed round of $4.7M announced in May 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
BriaCell Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2026.
BriaCell Therapeutics Funding Rounds
BriaCell Therapeutics raised $4.0M in an undisclosed round announced in May 2023.
1 years later, an undisclosed round of $5.0M was announced in May 2024.
4 months later, an undisclosed round of $8.5M was announced in Sep 2024.
3 months later, an undisclosed round of $5.5M was announced in Dec 2024.
2 months later, an undisclosed round of $3.1M was announced in Feb 2025.
5 months later, an undisclosed round of $15.0M was announced in Jul 2025.
6 months later, an undisclosed round of $30.0M was announced in Jan 2026.
4 months later, an undisclosed round of $4.7M was announced in May 2026.
BriaCell Therapeutics Founders and Leadership Team
Contact details for the BriaCell Therapeutics team: 2 of 2 have an email address on file.
Start 14-day free trial →BriaCell Therapeutics Funding Compared to Other Biotechnology Startups
BriaCell Therapeutics' latest round of $4.7M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like BriaCell Therapeutics in Biotechnology and New York
Companies Similar to BriaCell Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
BriaCell Therapeutics Funding FAQs
What does BriaCell Therapeutics do?
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. The company's patented immunotherapy Bria-IMT™ is developed from a breast cancer cell line is an immunotherapy approach that directly stimulates the body’s own cancer-fighting cells to attack and destroy breast cancer tumors. It induces an antitumor response both indirectly and directly by stimulating the immune system which collectively boosts the body’s response. BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™ in a combination with retifanlimab and epacadostat. The company is developing Bria-OTS™, the first “off the shelf” personalized immunotherapy for advanced breast cancer. It is founded in New York, New York in 2004.
How much funding has BriaCell Therapeutics raised?
BriaCell Therapeutics has raised $75.8M across 8 rounds on record. The most recent is an undisclosed round of $4.7M announced in May 2026.
When did BriaCell Therapeutics last raise funding?
BriaCell Therapeutics' most recent funding round on record is an undisclosed round of $4.7M, announced in May 2026.
Who founded BriaCell Therapeutics?
FundedIQ lists Charles Wiseman (Founder) at BriaCell Therapeutics.
Who is the CEO of BriaCell Therapeutics?
William Williams is listed as CEO at BriaCell Therapeutics.
Where is BriaCell Therapeutics headquartered?
BriaCell Therapeutics is based in New York, United States.
How many employees does BriaCell Therapeutics have?
BriaCell Therapeutics is in the 11-50 employee band.
How does BriaCell Therapeutics' funding compare to other Biotechnology startups?
BriaCell Therapeutics' latest round of $4.7M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's BriaCell Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for BriaCell Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.